

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **NOC2L RABBIT PAB**

货号: S217653

产品全名: NOC2L 兔多抗 基因符号 NIR; NET7; NET15

UNIPROT ID: Q9Y3T9 (Gene Accession - BC003555)

背景: Histone modification by histone acetyltransferases (HAT) and histone deacetylases (HDAC) can control major aspects of

transcriptional regulation. NOC2L represents a novel HDAC-independent inhibitor of histone acetyltransferase (INHAT)

抗原: Fusion protein of human NOC2L

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 25-100;WB: 200-1000;ELISA: 1000-2000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Epigenetics and Nuclear Signaling, Cancer

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human




In comparision with the IHC on the left, the same paraffin-embedded prostate cancer tissue using 217653(NOC2L Antibody) at a dilution of Human prostate cancer tissue is first treated with the fusion protein 1/20(Cytoplasm or Nucleus).


Human prostate cancer tissue is first treated with the fusion protein and then with 217653(Anti-NOC2L Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human breast cancer tissue using 217653(Anti-NOC2L Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D222774(Anti-NOC2L Antibody) at dilution 1/20.



Gel: 6%SDS-PAGE, Lysate: 40 µg;

Primary antibody: 217653(NOC2L Antibody) at dilution 1/200; Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;

Exposure time: 5 seconds



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010